ESMO 2024 Summary: Practice-Changing Trials for Patients With Localized MIBC - NIAGARA and AMBASSADOR

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

This video is featured in the 2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Practice-Changing Trials for Patients With Localized MIBC - NIAGARA and AMBASSADOR

By 2024 ESMO Annual Meeting Insights Hub FEATURING Petros Grivas

245 views

September 20, 2024

Comments 0

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma and Qual…

Feat. R. Alter, A. Rezazadeh

Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and …

Feat. K. Hanna, J. Strauss

2024 ESMO Annual Meeting Insights Hub: GU Videos

New

ESMO 2024 Summary: Developmental Therapeutics Highlights

2024 ESMO Annual Meeting Insights Hub

G. Sonpavde

251 views

3 weeks ago

ESMO 2024 Summary: Important GU Trials - EV-103 5-Year Follow-Up (la…

2024 ESMO Annual Meeting Insights Hub

E. Plimack

173 views

1 month ago

ESMO 2024 Summary: Key Trial Results in Advanced Bladder Cancer Trea…

2024 ESMO Annual Meeting Insights Hub

G. Sonpavde

154 views

1 month ago

View All

BLADDR 2024 - Hybrid Global Forum on GU Oncology

Wed, Nov 27, 2024

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

2024 ASCO® Annual Meeting Insights Hub

E. Hamilton

1.4K views

5 months ago

Recent GU Developments and Their Clinical Implications

Insights from 2024 ASCO® GU Annual Meeting

T. Powles, B. Rini

1.5K views

8 months ago

Bladder Cancer Highlights From ASCO® 2024

2024 ASCO® Annual Meeting Insights Hub

G. Sonpavde

1.4K views

5 months ago

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

1.9K views

7 months ago

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

1.2K views

7 months ago

Updates in the Treatment and Management of Bladder Cancer

Integrity CE

M. Galsky, B. Guercio

283 views

3 months ago

ESMO 2024 Summary: GU Practice-Changing Trial Results of PEACE-3 (mC…

2024 ESMO Annual Meeting Insights Hub

R. Dreicer

276 views

1 month ago

Best of Bladder Cancer and RCC From ESMO 2023 and GU ASCO 2024

Total Health

M. Reimers

529 views

8 months ago

Bladder Cancer Highlights From ESMO 2023: Comparing and Contrasting …

Insights from 2023 ESMO Annual Meeting

G. Sonpavde

853 views

1 year ago

ESMO 2024 Summary: Important GU Trials - EV-103 5-Year Follow-Up (la…

2024 ESMO Annual Meeting Insights Hub

E. Plimack

173 views

1 month ago

Developmental Therapeutics Highlights From ASCO® 2024

2024 ASCO® Annual Meeting Insights Hub

G. Sonpavde

533 views

4 months ago

New

ESMO 2024 Summary: Developmental Therapeutics Highlights

2024 ESMO Annual Meeting Insights Hub

G. Sonpavde

251 views

3 weeks ago

Urothelial Carcinoma: New Developments

Weill Cornell Medicine Oncology & Hematology

C. Sternberg

344 views

5 months ago

NCCN Guidelines Updates for the Treatment of Metastatic Urothelial C…

University of Colorado Cancer Center

T. Flaig

337 views

6 months ago

ASCO® 2024 Summary: "Bladder and RCC Highlights"

2024 ASCO® Annual Meeting Insights Hub

K. Tawagi, N. Reizine

263 views

4 months ago

Current Updates in Urothelial Cancer: Clinical Implications for Prac…

Kriti Mittal

402 views

8 months ago

ASCO® GU 2024 Summary: "Key Highlights in Bladder/Urothelial Carcino…

Insights from 2024 ASCO® GU Annual Meeting

G. Sonpavde

415 views

9 months ago

Trastuzumab Deruxtecan Approval for Metastatic HER2+ Bladder Cancer

UCSF School of Medicine

V. Koshkin

262 views

5 months ago

Sequencing 1L Therapies in Metastatic Urothelial Carcinoma

Scripps Health

P. Grivas

319 views

8 months ago

ESMO 2024 Summary: Important GU Trials - ETER100 (RCC), TACITO (mRCC…

2024 ESMO Annual Meeting Insights Hub

C. Porta

174 views

1 month ago

AUTOPLAY

Login

Login

Join VuMedi

ESMO 2024 Summary: Practice-Changing Trials for Patients With Localized MIBC - NIAGARA and AMBASSADOR

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma and Qual…

Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and …

2024 ESMO Annual Meeting Insights Hub: GU Videos

ESMO 2024 Summary: Developmental Therapeutics Highlights

ESMO 2024 Summary: Important GU Trials - EV-103 5-Year Follow-Up (la…

ESMO 2024 Summary: Key Trial Results in Advanced Bladder Cancer Trea…

Recommended

BLADDR 2024 - Hybrid Global Forum on GU Oncology

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

Recent GU Developments and Their Clinical Implications

Bladder Cancer Highlights From ASCO® 2024

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Hyperprogression in Cancer Treated With Immunotherapy

Updates in the Treatment and Management of Bladder Cancer

ESMO 2024 Summary: GU Practice-Changing Trial Results of PEACE-3 (mC…

Best of Bladder Cancer and RCC From ESMO 2023 and GU ASCO 2024

Bladder Cancer Highlights From ESMO 2023: Comparing and Contrasting …

ESMO 2024 Summary: Important GU Trials - EV-103 5-Year Follow-Up (la…

Developmental Therapeutics Highlights From ASCO® 2024

ESMO 2024 Summary: Developmental Therapeutics Highlights

Urothelial Carcinoma: New Developments

NCCN Guidelines Updates for the Treatment of Metastatic Urothelial C…

ASCO® 2024 Summary: "Bladder and RCC Highlights"

Current Updates in Urothelial Cancer: Clinical Implications for Prac…

ASCO® GU 2024 Summary: "Key Highlights in Bladder/Urothelial Carcino…

Trastuzumab Deruxtecan Approval for Metastatic HER2+ Bladder Cancer

Sequencing 1L Therapies in Metastatic Urothelial Carcinoma

ESMO 2024 Summary: Important GU Trials - ETER100 (RCC), TACITO (mRCC…